Adolescents and young adults with germline CDH1 variants and the risk of overtreatment
JNCI: Journal of the National Cancer Institute · 2025
DOI: 10.1093/jnci/djaf002 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Amber F Gallanis und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States. Hauptthemen laut MEDLINE: Stomach Neoplasms, Germ-Line Mutation, Cadherins, Antigens, CD. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural Research Program, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
Adolescents and young adults (AYA) with germline CDH1 variants are at risk of overtreatment when precancer lesions are detected with endoscopic screening. We characterize diffuse-type gastric cancer prevalence and survival in AYA managed with prophylactic total gastrectomy (PTG) or endoscopic surveillance.
Methods
Prospective cohort study of 188 individuals aged 39 and younger enrolled from January 27, 2017, to May 1, 2023. Clinicopathological data, prevalence of early gastric signet ring cell (SRC) lesions, advanced gastric cancer diagnoses, and cancer-specific survival were measured.
Results
Among 188 AYA patients, 104 chose surveillance and 67 pursued PTG for management of elevated gastric cancer risk. AYA who enrolled early in the study period and had SRC lesions detected on preoperative endoscopy were more likely to elect for PTG compared with surveillance. SRC lesions were detected on preoperative endoscopy in 48% of patients who subsequently had PTG, and yet nearly all (93%, 62/67) had multifocal SRC (pT1aN0) on final pathology. Median age at enrollment (30 vs 31 years, P = .21), biological sex (P = .17), and median number of family members with gastric cancer (3 vs 4, P = .14) were not different between groups. No patients under surveillance developed advanced cancer or developed cancer recurrence after PTG with a median follow-up of 2.5 years (IQR = 1.6-4.0) from initial endoscopy.
Conclusions
Cancer-specific outcomes were not different in AYA who harbored SRC and were managed with surveillance or PTG. Lack of cancer-specific deaths and low prevalence of advanced gastric cancer underscore the risk of overtreatment of SRC lesions and suggest that active surveillance is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
- Clinical Center Nutrition Department, National Institutes of Health, Bethesda, MD 20892, United States.
- Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
- Department of Pediatrics, National Institutes of Health Clinical Center, Bethesda, MD 20892, United States.
- Office of Patient Safety and Clinical Quality, National Institutes of Health Clinical Center, Bethesda, MD 20892, United States.
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
ORCID-Profile: Amber F Gallanis, Cassidy Bowden, Rachael Lopez, Grace-Ann Fasaye, David Lang, M Constanza Camargo, Anjali Rai, Theo Heller, Andrew M Blakely, Jeremy L Davis
Förderung
- Intramural Research Program
- NCI NIH HHS
- NIH HHS
- Stomach for Cancer, Inc.
- DLH Foundation
- Stupid Strong Charitable Foundation
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Gallanis, A. F., Bowden, C., Lopez, R., Fasaye, G. A., Lang, D., Rothschild, J., Camargo, M. C., Hernandez, J. M., Rai, A., Heller, T., Blakely, A. M., & Davis, J. L. (2025). Adolescents and young adults with germline CDH1 variants and the risk of overtreatment. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf002
Vancouver
Gallanis AF, Bowden C, Lopez R, Fasaye GA, Lang D, Rothschild J, et al. Adolescents and young adults with germline CDH1 variants and the risk of overtreatment. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djaf002
BibTeX
@article{Gallanis2025,
author = {Gallanis, Amber F and Bowden, Cassidy and Lopez, Rachael and Fasaye, Grace-Ann and Lang, David and Rothschild, Jill and Camargo, M Constanza and Hernandez, Jonathan M and Rai, Anjali and Heller, Theo and Blakely, Andrew M and Davis, Jeremy L},
title = {Adolescents and young adults with germline CDH1 variants and the risk of overtreatment},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
doi = {10.1093/jnci/djaf002}
}
EUVIMED